title: Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia?
abstract: BACKGROUND
  Previous studies analyzed the ability of hippocampal volumes (HV) to differentiate Alzheimer's disease (AD) from frontotemporal dementia (FTD). However, these studies did not include patients selected according to clinico-biological criteria, using pathophysiological biomarkers.
  
  
  OBJECTIVE
  To analyze the effectiveness of hippocampal volumetric measures to distinguish AD from behavioral variant FTD (bvFTD), using strict inclusion criteria based on clinical and pathophysiological markers.
  
  
  METHODS
  Seventy-two participants were included: 31 AD patients with predominant and progressive episodic memory deficits associated with typical AD cerebrospinal fluid (CSF) profile and/or positive amyloid imaging (PET with 11C-labeled Pittsburgh Compound B [PiB]), 26 bvFTD patients diagnosed according to consensual clinical criteria and with no AD CSF profile, and 15 healthy controls without amyloid retention on PiB-PET exam. HV were segmented with an automated method and were normalized to total intracranial volume (nHV).
  
  
  RESULTS
  Significant reductions in HV were found in both AD and bvFTD patients compared with controls, but there were no significant difference between AD and bvFTD patients. Mean nHV distinguished normal controls from either AD or bvFTD with high sensitivity (80.6% and 76.9%, respectively) and specificity (93.3% for both), but it was inefficient in differentiating AD from bvFTD (9.7% specificity). There was no difference in the clinical and neuropsychological profiles according to HV in bvFTD and AD patients.
  
  
  CONCLUSIONS
  When considered alone, measures of HV are not good markers to differentiate AD from bvFTD. Hippocampal sclerosis associated with FTD may explain the high degree of overlap in nHV between both groups.
authors.affiliation: CRICM, UPMC Univ Paris 06, INSERM, UMR-S 678, Paris, France.
authors.forename: Leonardo Cruz
authors.initials: LC
authors.lastname: de Souza
authors.forename: Marie
authors.initials: M
authors.lastname: Chupin
authors.forename: Maxime
authors.initials: M
authors.lastname: Bertoux
authors.forename: Stéphane
authors.initials: S
authors.lastname: Lehéricy
authors.forename: Bruno
authors.initials: B
authors.lastname: Dubois
authors.forename: Foudil
authors.initials: F
authors.lastname: Lamari
authors.forename: Isabelle
authors.initials: I
authors.lastname: Le Ber
authors.forename: Michel
authors.initials: M
authors.lastname: Bottlaender
authors.forename: Olivier
authors.initials: O
authors.lastname: Colliot
authors.forename: Marie
authors.initials: M
authors.lastname: Sarazin
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000473:pathology; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001921:Brain / Q000473:pathology; D016022:Case-Control Studies; D003937:Diagnosis, Differential; D005260:Female; D057180:Frontotemporal Dementia / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000473:pathology; D006624:Hippocampus / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D059906:Neuroimaging; D009929:Organ Size; D049268:Positron-Emission Tomography; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D015415:Biomarkers; D016875:tau Proteins